| 产品描述: | PYZD-4409 is a specific inhibitor of the ubiquitin-activating enzyme UBA1 with an IC50 of 20 μM (cell-free enzymatic assay). PYZD-4409 induces cell death in malignant cells and preferentially inhibits the clonogenic growth of primary acute myeloid leukemia cells |
| 靶点: |
IC50: 20 μM (ubiquitin-activating enzyme UBA1);E1/E2/E3Enzyme |
| 体外研究: |
PYZD-4409 (10-40 μM; 72 hours; myeloma, leukemia, and solid tumor cell lines, primary AML cells and normal hematopoietic cells) induces cell death with a LD50 less than 10 μM in 5 of 8 leukemia and myeloma cell lines. In contrast, solid tumor cell lines were less sensitive with an LD50 of approximately 15 to 20 μM. PYZD-4409 is preferentially cytotoxic to malignant cells over normal hematopoietic cells. PYZD-4409 (50 μM; 4 hours; K562 leukemia cells) treatment blocks the E1-dependent conjugation of ubiquitin to the E2 enzyme cdc34. PYZD-4] protein levels of Grp78 and Hsp70. In addition, PYZD-4409 increases levels of phospho-JNK and phospho-p38 mitogen-activated protein kinase, which have also been linked to ER stress and the unfolded protein response. Cell Cytotoxicity Assay Cell Line: Myeloma, leukemia, and solid tumor cell lines, primary AML cells and normal hematopoietic cells Concentration: 10 μM, 20 μM, 30 μM, 40 μM Incubation Time: 72 hours Result: Induced cell death with a LD50 less than 10 μM in 5 of 8 leukemia and myeloma cell lines. In contrast, solid tumor cell lines were less sensitive with an LD50 of approximately 15 to 20 μM. Western Blot Analysis Cell Line: K562 leukemia cells Concentration: 50 μM Incubation Time: 4 hours Result: Blocked the E1-dependent conjugation of ubiquitin to the E2 enzyme cdc34. RT-PCR Cell Line: K562 cellsConcentration: 0 μM, 10 μM, 25 μMIncubation Time: 24 hoursResult: Significantly increased both mRNA and protein levels of Grp78 and Hsp70. |
| 体内研究: |
PYZD-4409 (10 mg/kg; intraperitoneal injection; daily on alternate days; for 16 days; male severe combined immunodeficient mice) decreases tumor weight and volume without untoward toxicity. Animal Model: Male severe combined immunodeficient (SCID) mice with MDAY-D2 murine leukemia cells Dosage: 10 mg/kg Administration: Intraperitoneal injection; daily on alternate days; for 16 days Result: Delayed tumor growth and decreased tumor weight without untoward toxicity. |
| 参考文献: |
1. Xu GW, et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood. 2010 Mar 18;115(11):2251-9. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.844 ml |
14.218 ml |
28.435 ml |
| 5 mM |
0.569 ml |
2.844 ml |
5.687 ml |
| 10 mM |
0.284 ml |
1.422 ml |
2.844 ml |
| 50 mM |
0.057 ml |
0.284 ml |
0.569 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |